Loading...

VYGR VOYAGER THERAPEUTICS INC US FDA Inspections 8-K Filing

VYGR

VYGR

VOYAGER THERAPEUTICS INC

(VYGR)

2024 8-K

Show Summary

Show Summary

Financial Statements

Financial Results

ALS Program Update

Q3 Financial Results

License Agreement Update

Earnings Reports

Appointment of CFO

Annual Meeting of Stockholders

Phase 1a Trial Announcement

Financial Results

Departure of CFO and Appoin...

Appointment of Chief Medica...

Financial Results and Updates

Public Offering

License and Collaboration A...

Financial Results

Lease Agreement Amendment

Earnings Reports

Annual Meeting of Stockholders

Financial Results

Appointment of Director

Cash Holdings at Silicon Va...

Financial Results

Appointment of Director

Departure of Directors or C...

Collaboration Agreement

External Links:

Voyager Therapeutics announced the start of a Phase 1a trial for VY-TAU01, an anti-tau antibody for Alzheimer's disease.

AI Assistant

VOYAGER THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.